ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Association of smoking with serum uric acid levels, hyperuricemia, and gout based on the 7th to 9th Korea National Health and Nutrition Examination Survey: A secondary dataset analysis based on a cross-sectional study. [PDF]
Kim S.
europepmc +1 more source
Potential Similarity of Serum Cholesterol Multivariate Coefficients in the Prediction of Coronary Heart Disease Across Populations: A Review From the Seven Countries Study. [PDF]
Menotti A, Puddu PE.
europepmc +1 more source
Preoperative hypocalcemia predicts postoperative complications in older orthopedic patients: A multicenter cohort study. [PDF]
Li D +5 more
europepmc +1 more source
Systematic review of ocular and circulatory cytokines linking diabetic retinopathy to kidney disease. [PDF]
Tang Y, Li Z, Jia Z.
europepmc +1 more source
Diagnostic and prognostic utility of serum β-synuclein in Alzheimer's disease: a longitudinal cohort study. [PDF]
Xie S +6 more
europepmc +1 more source

